A PROSPECTIVE, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF CLAZOSENTAN IN PREVENTING CLINICAL DETERIORATION DUE TO DELAYED CEREBRAL ISCHEMIA (DCI), IN ADULT SUBJECTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE (ASAH)

Registry ID

ID-054-304

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

IDORSIA PHARMACEUTICALS LTD

Start date

2019-06-28

Last update

2018-08-21

Conditions

• ANEURYSMAL SUBARACHNOID HEMORRHAGE

Related clinical trials

• PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY COMPARING EG-1962 TO STANDARD OF CARE ORAL NIMODIPINE IN ADULTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE

View on source registry